Hansoh BioMedical R&D Company Drug Pipeline

Hansoh BioMedical R&D Company maintains a substantial clinical development portfolio, with 36 trials registered since 2008 and 34 currently active. The pipeline spans early- to late-stage development, comprising 16 active Phase 1 trials, 13 in Phase 2, and 8 in Phase 3. The company’s research is heavily concentrated in Oncology, which accounts for 31 active trials, representing 91% of the active portfolio. Within Oncology, a significant portion of the activity focuses on Solid Tumors (Advanced), with 12 active trials, though none are in Phase 3. The next most active indications are Non-Small Cell Lung Cancer (NSCLC) with 4 active trials, including 2 in Phase 3; Sarcoma with 3 active trials, including 1 in Phase 3; Colorectal Cancer with 3 active trials; and Ovarian Cancer with 2 active trials, including 1 in Phase 3. Immunology represents the other major therapeutic area, with 4 active trials. The weighting toward Phase 3 trials in NSCLC, Sarcoma, and Ovarian Cancer suggests potential near-term clinical catalysts within the Oncology program.